Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.
Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.
复制标题
DOI：
--
复制
发表时间：
1997-12
期刊：
影响因子：
11.2
通讯作者：
B. Lannutti;S. Gately;M. Quevedo;G. Soff;A. Paller
中科院分区：
文献类型：
--
作者：
B. Lannutti;S. Gately;M. Quevedo;G. Soff;A. Paller
血管抑制素抑制血管生成和转移性肿瘤生长，然而，它在治疗原发性非转移性肿瘤的有效性还不太清楚。我们现在报告的有效性，人血管抑素管理在小鼠血管内皮瘤模型。将人血管抑制素给予具有s.c.血管内皮瘤和相关的弥散性血管内凝血病（Kasabach-Merritt综合征）。与未治疗的对照组相比，血管抑素显著减小了肿瘤体积，增加了生存率，并预防了Kasabach-Merritt综合征的严重血小板减少和贫血。血管抑素可诱导肿瘤细胞凋亡，但不能抑制肿瘤细胞增殖。这些数据表明，血管抑素作为一种新的治疗非转移性血管肿瘤和Kasabach-Merritt综合征。
Angiostatin inhibits angiogenesis and metastatic tumor growth; however, its usefulness in treating primary nonmetastasizing tumors is less well understood. We now report the effectiveness of human angiostatin administration in a mouse hemangioendothelioma model. Human angiostatin was administered to mice with s.c. hemangioendothelioma and associated disseminated intravascular coagulopathy (Kasabach-Merritt syndrome). Angiostatin significantly reduced tumor volume in comparison to nontreated controls, increased survival, and prevented the profound thrombocytopenia and anemia of Kasabach-Merritt syndrome. Apoptosis of tumor cells was induced by angiostatin, but tumor cell proliferation was not inhibited. These data suggest angiostatin as a novel treatment for nonmetastasizing vascular tumors and for Kasabach-Merritt syndrome.